GLP ‐1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real‐World Study of Lifestyle Pre‐Treatment, Time‐Limited Treatment Cap, and Post‐Cessation Regain
Diabetes, Obesity and Metabolism · Published 2026-08-04 · DOI 10.1111/dom.71190
Free full text
Authors (2)
Susumu Inamine, Yasunori Uesato
Abstract
PubPorta does not have an abstract for this article yet.
Read the article at the publisher →
Publication details
- Year
- 2026
Citation
Inamine, S., Uesato, Y. (2026). GLP ‐1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real‐World Study of Lifestyle Pre‐Treatment, Time‐Limited Treatment Cap, and Post‐Cessation Regain. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71190
Related articles
- Economic Impact of Multidisciplinary Pre‐operative Diabetes Care Versus Usual Care in Adults Undergoing Elective Non‐cardiac Surgery in Australia: A Trial‐Based Analysis · Diabetes, Obesity and Metabolism · 2026 · Same journal
- Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease · Diabetes, Obesity and Metabolism · 2026 · Same journal
- Metformin Ameliorates Diabetes‐Associated Cognitive Dysfunction via p53/Parkin‐Mediated Mitophagy · Diabetes, Obesity and Metabolism · 2026 · Same journal
- Trends and Prevalence of Undiagnosed Dysglycemia Among Reproductive‐Age Women in the United States · Diabetes, Obesity and Metabolism · 2026 · Same journal
- Beyond Glycaemia: Fear of Hypoglycaemia, Cognition and Functional Mobility After Advanced Hybrid Closed‐Loop Therapy in Older Adults With Type 1 Diabetes: A Prespecified Secondary Analysis of a Randomised, Single‐Centre Study · Diabetes, Obesity and Metabolism · 2026 · Same journal
- Diagnostic Yield of Structured Cushing Syndrome Evaluation in Treatment‐Resistant Non‐Diabetic Obesity: A Retrospective Pilot Study · Diabetes, Obesity and Metabolism · 2026 · Same journal
- Exercise Snacks Are Feasible to Perform in the Real World and Improve Physical Capacity for Adults Living With Non‐Insulin Treated Type 2 Diabetes: A Randomised Trial · Diabetes, Obesity and Metabolism · 2026 · Same journal
- Real‐World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study ( MEDFINE ‐ RWD ) · Diabetes, Obesity and Metabolism · 2026 · Same journal
- Sodium Butyrate Attenuates Renal Fibrosis by Regulating Glycolysis and Histone H4K12 Lactylation in Diabetic Kidney Disease · Diabetes, Obesity and Metabolism · 2026 · Same journal
- Methodological and Conceptual Concerns Regarding the 24‐h Glycaemia/C‐Peptide Ratio as a Novel Insulin Sensitivity Index · Diabetes, Obesity and Metabolism · 2026 · Same journal